Firms want to license reactome array


Madrid – Responding to the current debate surrounding the reactome array investigation, Manuel Ferrer from the Institute of Catalysis and Petrochemistry in Madrid told EuroBiotechNews his team would “clarify all the scientific issues concerning the biochip with a new paper.“ But economic matters could soon overtake scientific redemption. Several large companies are interested in the revolutionary biochip, Ferrer said, and will soon begin with testing. This even though the authors withdrew the original publication in August due to reputed errors in the general reaction scheme of the chip.
In October 2009, Ferrer presented a novel technique he and co-authors claimed would herald “a new age of discovery“ in medicine and chemistry (Science, 326 (5950), 252-257). Their react­ome array is a tiny glass slide carrying 1,676 individual enzyme substrates that represent the metabolic pathways of all forms of life.

When a specific enzyme in a cell or bacterial lysate reacts with its cognate substrate on the array surface, a substrate-linked, fluorescence-quenched Cy3 dye begins to glow. Subsequent isolation of the appropriate enzyme is possible with the help of tiny gold beads that carry multiple copies of the substrate on its surface. However, after publication, several organic chemists raised questions about the feasibility of the claim. The doubts led to an editorial expression of concern. The rumours didn’t abate, and in August of 2010, ethical committees at three of the involved research centres finally urged the authors to retract the paper. They eventually complied. But marine microbiologists who have worked with the chip to verify computational predictions of gene functions generated by DNA sequencing are enthusiastic about the array. They said it allowed them to confirm more than 300 putative gene functions. “The patent application has been corrected and there is huge interest from the industry,” adds Sabina Heim from the patent agency Ascenion.
For Ferrer the retraction is not the end of the story, but the beginning of the next round. He says he will follow a three-pronged approach to the issue. First, several international pharmaceutical and biotechnology companies will be taking a serious look at the device, he told EuroBiotechNews. The patent application is pending, and should be published in September. Second, Ferrer says he is working on a new paper which will “focus on chemistry“, adding that “this time there will be a proper chemical analysis, just to avoid any misunderstandings.“ The third pathway Ferrer is following to reestablish faith in the reactome array is collaboration with other scientific groups.



Granada-based Integromics S.L. has teamed up with the Galician Foundation of Genomic Medicine (FPGMX) in Santiago de Compostela to secure a €1m EU grant from the European Regional Development Fund and the Spanish government. With...



Oryzon Genomics S.A (Barcelona) is entering preclinical testing with a first-in-class bispecific LSD1/MAO-B inhibitor. In addition to the classic target MAO-B, the drug also blocks histone demethylase LSD1, an epigenetic histone...



Granada-based nLife Therapeutics S.L. has raised €5m in total from two venture capitalists. Through Caixa Capital Risc and Caixa Capital Biomed, La Caixa invested €2.5m. The same amount has been placed by Invercaria via its...



Ordesa Laboratories has filed a patent for a novel Bifidobacterium strain isolated from infant feces. It has the capacity to combat rotavirus, says a study (Appl. Environ. Microbiol., doi:10.1128/AEM.05548).



Madrid – Researchers from Spain and the US have discovered an Ebola-like filovirus in bats in northern Spain. The first known filovirus native to Europe was reported in a study published in the journal PLOS Pathogens...



Barcelona - South western Europe gets a new R&D unit in the field of biomolecules. Kymos Pharma, a contract researcher based in Barcelona, has signed an agreement with the French biotechnology group Ipsen to create a R&D group...



Barcelona/Saffron Walden – Almirall S.A. and BioFocus announced that they have entered into a collaboration agreement to identify new compounds against key targets in projects aimed at the treatment of respiratory and...



Madrid/Abu Dhabi – Spanish biotechs are seeking collaborations with firms in the United Arab Emirates. At the end of November, Grupo Zeltia and 14 other Spanish companies presented their research at the forum “Innovation,...



Madrid – The Spanish Minister of Innovation and Science Cristina Garmendia has responded to reports about Roche’s­ delivery stop in Greece and pessimistic expectations for Spain. In Sept­ember, she stressed that the atmosphere...

Displaying results 1 to 10 out of 181

1-10 Next >

© 2007-2015 BIOCOM

Current issue

All issues


All videos

Product of the week


Stock list

All quotes


  • DIAMYD MEDICAL -B- (S)10.00 SEK14.29%
  • SERODUS (N)2.67 NOK9.43%


  • EVOCUTIS (UK)0.09 GBP-10.00%
  • VERONA PHARMA (UK)3.05 GBP-6.15%
  • SAREUM HOLDINGS (UK)0.19 GBP-5.00%


  • PLETHORA (UK)5.62 GBP80.1%
  • PROTHENA PLC (IE)73.19 USD40.9%
  • CELLECTIS (F)30.70 EUR32.3%


  • EPIGENOMICS (D)1.87 EUR-58.5%
  • EVOCUTIS (UK)0.09 GBP-40.0%


  • KARO BIO (S)38.10 SEK5342.9%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)45.70 EUR254.3%


  • BIOTEST (D)15.34 EUR-81.0%
  • EVOCUTIS (UK)0.09 GBP-78.6%

No liability assumed, Date: 26.11.2015


All Events


Strasbourg (F)

BioFIT 2015